Biotech | January 11, 2022
Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
The company has developed the API in house at its R&D center in Hyderabad
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Subscribe To Our Newsletter & Stay Updated
